Background
Twice-yearly subcutaneous lenacapavir (LEN) demonstrated high efficacy and favorable safety in two Phase 3 trials (PURPOSE 1 and 2) conducted in a diverse population of people who would benefit from pre-exposure prophylaxis (PWBP), facilitating approval in the US and EU. Extending the LEN dosing interval to once-yearly has the potential to further improve pre-exposure prophylaxis (PrEP) uptake and persistence. We report a model-informed drug development (MIDD) approach for the dose selection and design of a Phase 3 trial evaluating once-yearly intramuscular (IM) LEN for PrEP using population pharmacokinetic (popPK) modeling.
Methods
A 3-compartment popPK model was developed using data from 4 Phase 1 trials with a total of 151 participants and 3378 LEN concentration measurements. Oral data included doses from 300 to 1800 mg and IM data included a single dose of 5000 mg. We used this model to perform simulations investigating various oral loading frequencies and potential IM doses. The simulations leveraged the large size and diverse population characteristics of the PURPOSE trials to select a regimen projected to maintain protective concentrations across PWBP for at least 52 weeks. Dose selection was based on exposure matching, targeting a dose where the Week 52 Ctrough was projected to be equivalent to or greater than the observed Week 26 Ctrough in PURPOSE 1 and 2.
Results
PopPK simulations predicted that an IM dose of 3000 mg would result in a Week 52 Ctrough exceeding the observed Week 26 Ctrough in PURPOSE 1 and 2. This dose is also projected to maintain mean LEN concentration (and 90% confidence interval) above four times the in vitro inhibitory quotient 4 (IQ4; 15.5 ng/mL) for ≥ 52 weeks. Simulations indicated that oral loading (600 mg on Days 1 and 2) is needed to achieve target concentrations rapidly by Day 2. To assess safety and facilitate MIDD-based efficacy extrapolation, we initiated a single-arm, open-label Phase 3 study in which 300 diverse PWBP will receive 3000 mg of LEN (two 3-mL, ventrogluteal IM injections) once-yearly (PURPOSE 365; NCT07047716).
Conclusions
A dose of 3000 mg IM for once-yearly LEN was determined based on popPK modeling. The MIDD-based approach allows for an expedited development strategy, wherein by matching exposures, efficacy can then be extrapolated from twice-yearly LEN data without a large efficacy-powered Phase 3 study.